Journalartikel

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension


AutorenlisteWiedenroth, Christoph B.; Ghofrani, H. Ardeschir; Adameit, Miriam S. D.; Breithecker, Andreas; Haas, Moritz; Kriechbaum, Steffen; Rieth, Andreas; Hamm, Christian W.; Mayer, Eckhard; Guth, Stefan; Liebetrau, Christoph

Jahr der Veröffentlichung2018

ZeitschriftPulmonary Circulation

Bandnummer8

Heftnummer3

ISSN2045-8932

eISSN2045-8940

Open Access StatusGold

DOI Linkhttps://doi.org/10.1177/2045894018783996

VerlagWiley


Abstract
Riociguat is the treatment of choice for inoperable patients with chronic thromboembolic pulmonary hypertension (CTEPH). We addressed here whether additional balloon pulmonary angioplasty (BPA) provides further benefits. A prospective series of 36 consecutive patients with inoperable CTEPH were treated with riociguat at least three months before BPA. All patients underwent diagnostic workup at baseline, before BPA treatments, and six months after final intervention. The main outcome measures were pulmonary hemodynamic parameters and World Health Organization (WHO) functional class (FC). Significant improvements in pulmonary hemodynamics and physical capacity were observed for riociguat treatment, and subsequent BPA interventions yielded further benefits. With targeted medication, WHO FC improved by at least one class in 13 (36.1%) patients (P=0.01). Hemodynamic assessment showed significant improvements in mean pulmonary arterial pressure (mPAP) (49 +/- 12 mmHg vs. 43 +/- 12 mmHg; P = 0.003) and PVR (956 +/- 501 dyn.s.cm(-5 )vs. 517 +/- 279 dyn.s.cm -s ; P= 0.0001). Treatment with a combination of targeted medication and BPA resulted in WHO FC improvement in 34 (94.4%) patients. Hemodynamic assessment showed significant improvement in mPAP (43 +/- 12 mmHg vs. 34 +/- 14 mmHg; P= 0.0001) and PVR (517 +/- 279 dyn.s.cm(-5) vs. 360 +/- 175 dyn.scm(-5); P=0.0001). These findings provide, for the first time, support for the therapeutic strategy recommended by current guidelines.



Zitierstile

Harvard-ZitierstilWiedenroth, C., Ghofrani, H., Adameit, M., Breithecker, A., Haas, M., Kriechbaum, S., et al. (2018) Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension, Pulmonary Circulation, 8(3), Article 2045894018783990. https://doi.org/10.1177/2045894018783996

APA-ZitierstilWiedenroth, C., Ghofrani, H., Adameit, M., Breithecker, A., Haas, M., Kriechbaum, S., Rieth, A., Hamm, C., Mayer, E., Guth, S., & Liebetrau, C. (2018). Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulmonary Circulation. 8(3), Article 2045894018783990. https://doi.org/10.1177/2045894018783996



Schlagwörter


BALLOON PULMONARY ANGIOPLASTYChronic thromboembolic pulmonary hypertensionLONG-TERM EXTENSIONOPEN-LABELPREDICTORSRIOCIGUATtargeted medication


Nachhaltigkeitsbezüge


Zuletzt aktualisiert 2025-10-06 um 10:53